Drug Trial Radar · NCT07174687
SGLT2 Inhibitors in Geographic Atrophy
Last checked: Nov 20, 2026Latest source record: Aug 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
70
Planned (sponsor's estimate)
Start
Dec 2, 2025
Primary completion
Dec 2027
Study completion Jun 2028
Sponsor
- Lead sponsor
- Washington University School of MedicineAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Sep 16, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
AMD is a leading cause of blindness in individuals over 50 years old, with dry AMD being the most common form. Geographic atrophy (GA) is an advanced stage of dry AMD characterized by progressive retinal cell degeneration. The primary objectives of the study are to assess the safety, tolerability, and evidence of activity of SGLT2 inhibitors in subjects with Geographic Atrophy associated with AMD.
Conditions
- Retinal Degeneration
- Retinal Diseases
- Eye Diseases
- Geographic Atrophy
- Pathological Conditions, Anatomical
Interventions
DapagliflozinDrug
Dapagliflozin is an SGLT2 inhibitor used in diabetes, heart failure, and chronic kidney disease patients.
Matching PlaceboOther
Matching oral placebo to dapagliflozin
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean Change From Baseline in Square Root GA Lesion Size in the Study Eye at Month 12Time frame: Baseline (screening) and Month 12.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Washington University
St Louis, Missouri · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.